Reference health

The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?

https://doi.org/10.2139/ssrn.1003132
CiteStamped reference-health badge
1 of 18 checkable references need attention · checked 2026-08-27

At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.

6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

References needing attention

does not resolve to a known work10.1162/105864097567039
The 17 checked references that resolve
resolves10.1086/386275
On the Incidence and Variety of Low‐Price Guarantees
resolves10.2307/2534748
Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs
resolves10.3386/w7024
Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
resolves10.2307/2534790
Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry
resolves10.7208/chicago/9780226132303.003.0012
Hedonic Analysis of Arthritis Drugs
resolves10.1086/467458
Does Regulation Drive Out Competition in Pharmaceutical Markets?
resolves10.1016/s0167-6296(99)00039-9
Cross-national price differences for pharmaceuticals: how large, and why?
resolves10.1377/hlthaff.w3.521
Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries
resolves10.1377/hlthaff.25.5.1353
Prices And Availability Of Biopharmaceuticals: An International Comparison
resolves10.2139/ssrn.1001884
R&D in the Pharmaceutical Industry: A World of Small Innovations
resolves10.1162/003465303765299828
Pharmaceutical Pricing in a Regulated Market
resolves10.2307/1060523
Pricing, Patent Loss and the Market for Pharmaceuticals
resolves10.1093/ww/9780199540884.013.15460
Farnell, John Bernard Patrick, (born 24 Aug. 1948), writer and researcher on China-EU economic relations; Director, Coordination and International Affairs, Enterprise and Industry Directorate-General, European Commission, 2008–12 (Director, Competitiveness, 2006–07)
resolves10.1086/467257
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
resolves10.2307/2555546
Facilitating Practices: The Effects of Advance Notice and Best-Price Policies
resolves10.1162/003465398557212
Strategic Pricing of New Pharmaceuticals
resolves10.2307/1913646
On the Pooling of Time Series and Cross Section Data
The 6 references without a DOI — listed, not checked
no DOI — not checkedref2
no DOI — not checkedPrice controls and entry strategy
no DOI — not checkedThe Pharmaceutical Industry
no DOI — not checkedMeasuring Quality Change in the Market for Anti-Ulcer Drugs
no DOI — not checkedref23
no DOI — not checkedref24
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-08-27 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.2139/ssrn.1003132"><img src="https://citestamp.com/citestamped/10.2139/ssrn.1003132/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.2139/ssrn.1003132/badge.svg)](https://citestamp.com/citestamped/10.2139/ssrn.1003132)